Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.43 |
| ▸ | LCK | P06239 | 5/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 6/20 | 0.43 |
| ▸ | EML4 | Q9HC35 | 3/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.42 |
| ▸ | SYK | P43405 | 6/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | ROS1 | P08922 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16206874 | 0.89 | BTK (0.55) | BTKLCKEGFRJAK3EML4 | |
| SCHEMBL16195649 | 0.88 | ALK (0.45) | BTKLCKJAK3EML4ALK | |
| SCHEMBL16195774 | 0.86 | EML4 (0.47) | BTKLCKEGFRJAK3EML4 | |
| SCHEMBL16206801 | 0.79 | BTK (0.49) | BTKLCKEGFRJAK3EML4 | |
| SCHEMBL14956008 | 0.78 | SYK (0.65) | EML4ALKSYKRETROS1 | |
| SCHEMBL17690654 | 0.76 | EML4 (0.53) | BTKLCKJAK3EML4ALK | |
| SCHEMBL16206875 | 0.75 | BTK (0.57) | BTKLCKEGFRJAK3EML4 | |
| SCHEMBL16206876 | 0.75 | BTK (0.55) | BTKLCKEGFRJAK3EML4 | |
| SCHEMBL10129765 | 0.75 | ALK (0.56) | EML4ALKSYKRETROS1 | |
| SCHEMBL10129630 | 0.75 | ALK (0.49) | BTKLCKJAK3EML4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805940-B1 | PYRAZINE CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| EP-2805940-A1 | PYRAZINE CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | EGFR, ERBB2, ALK | BTK 95/4885LCK 52/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.